Morgan Stanley
SYRE icon

Morgan Stanley’s Spyre Therapeutics SYRE Stock Holding History

Morgan Stanley’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Buy
246,719
+63,985
+35% +$2.41M ﹤0.01% 3381
2025
Q4 		$5.99M Sell
182,734
-151,988
-45% -$3.97M ﹤0.01% 4044
2025
Q3 		$5.61M Sell
334,722
-336,322
-50% -$5.48M ﹤0.01% 4064
2025
Q2 		$10M Buy
671,044
+335,577
+100% +$4.97M ﹤0.01% 3438
2025
Q1 		$5.41M Buy
335,467
+80,211
+31% +$1.67M ﹤0.01% 3862
2024
Q4 		$5.94M Buy
255,256
+11,514
+5% +$338K ﹤0.01% 3858
2024
Q3 		$7.17M Sell
243,742
-165,111
-40% -$4.6M ﹤0.01% 3680
2024
Q2 		$9.61M Buy
408,853
+357,665
+699% +$12.1M ﹤0.01% 3353
2024
Q1 		$1.94M Buy
51,188
+51,108
+63,885% +$1.48M ﹤0.01% 4605
2023
Q4 		$1.72K Buy
80
+34
+74% +$468 ﹤0.01% 7149
2023
Q3 		$564 Sell
46
-86
-65% -$1.14K ﹤0.01% 7296
2023
Q2 		$1.49K Sell
132
-414
-76% -$1.96K ﹤0.01% 7238
2023
Q1 		$3.96K Sell
546
-2,672
-83% -$29.3K ﹤0.01% 7112
2022
Q4 		$36.2K Sell
3,218
-3,512
-52% -$63.1K ﹤0.01% 6429
2022
Q3 		$88K Sell
6,730
-5,023
-43% -$62K ﹤0.01% 6145
2022
Q2 		$148K Buy
11,753
+4,485
+62% +$157K ﹤0.01% 6049
2022
Q1 		$418K Sell
7,268
-581
-7% -$48.8K ﹤0.01% 5513
2021
Q4 		$932K Buy
7,849
+80
+1% +$12.6K ﹤0.01% 5123
2021
Q3 		$1.54M Sell
7,769
-52
-0.7% -$9.1K ﹤0.01% 4772
2021
Q2 		$1.36M Buy
7,821
+3,377
+76% +$614K ﹤0.01% 4908
2021
Q1 		$880K Sell
4,444
-680
-13% -$130K ﹤0.01% 4814
2020
Q4 		$1.01M Buy
5,124
+3,720
+265% +$771K ﹤0.01% 4664
2020
Q3 		$249K Buy
1,404
+385
+38% +$71.2K ﹤0.01% 4993
2020
Q2 		$235K Buy
1,019
+881
+638% +$168K ﹤0.01% 4999
2020
Q1 		$16K Sell
138
-1,307
-90% -$222K ﹤0.01% 5890
2019
Q4 		$276K Buy
1,445
+1,120
+345% +$220K ﹤0.01% 5266
2019
Q3 		$63K Sell
325
-1,648
-84% -$321K ﹤0.01% 5616
2019
Q2 		$337K Buy
1,973
+1,621
+461% +$280K ﹤0.01% 4794
2019
Q1 		$71K Sell
352
-727
-67% -$152K ﹤0.01% 5528
2018
Q4 		$202K Sell
1,079
-114
-10% -$24.2K ﹤0.01% 5282
2018
Q3 		$285K Sell
1,193
-419
-26% -$97.9K ﹤0.01% 5289
2018
Q2 		$427K Buy
1,612
+1,315
+443% +$324K ﹤0.01% 5204
2018
Q1 		$73K Buy
297
+176
+145% +$31.8K ﹤0.01% 5791
2017
Q4 		$16K Hold
121
– – ﹤0.01% 6136
2017
Q3 		$15K Buy
121
+10
+9% +$937 ﹤0.01% 6102
2017
Q2 		$11K Buy
111
+2
+2% +$277 ﹤0.01% 6221
2017
Q1 		$20K Hold
109
– – ﹤0.01% 6090
2016
Q4 		$12K Sell
109
-43
-28% -$6.27K ﹤0.01% 6119
2016
Q3 		$25K Buy
+152
New +$21.1K ﹤0.01% 5843

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Morgan Stanley's SYRE Position: Q1 2026 in Review

Morgan Stanley increased its Spyre Therapeutics (SYRE) stake by 35% in Q1 2026, buying an estimated $2.41M and bringing the position to 246,719 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3381.

Morgan Stanley first reported a position in SYRE in Q3 2016 and has held it in 39 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Morgan Stanley held 246,719 shares of Spyre Therapeutics worth $12.4M as of Q1 2026.
  • Morgan Stanley bought 63,985 Spyre Therapeutics shares in Q1 2026, an estimated $2.41M.
  • Spyre Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3381 holding.
  • Morgan Stanley first reported a position in Spyre Therapeutics in Q3 2016 and has held it in 39 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.